Thyroid Eye Disease

We last featured thyroid eye disease in our June 10, 2021, issue of Healio | OSN. Interested readers might enjoy reviewing that cover story and my perspective.

Adults with long-standing thyroid eye disease and low clinical activity scores had greater reductions in proptosis with teprotumumab compared with placebo, according to data published in The Journal of Clinical Endocrinology & Metabolism.

The risk for thyroid eye disease is 3.2 times higher in adults, particularly those aged younger than 50 years, 28 days after receiving a vaccination against COVID-19.

Adults may have an increased risk for new-onset or recurrent thyroid eye disease in the 28 days after receiving a COVID-19 vaccine dose, according to findings published in The Journal of Clinical Endocrinology & Metabolism.

Both teprotumumab and tocilizumab reduce inflammation and thyroid eye disease severity, including among adults who were nonresponders to steroid treatment, according to findings published in Thyroid.

Thyroid eye disease is a debilitating, inflammatory autoimmune condition associated with Graves’ disease that is hard for patients, both physically and psychologically.

There are approximately 500 full-time fellowship-trained neuro- ophthalmologists in the U.S. to care for a population of 337 million, or about one per 675,000 population.

Dry eye in thyroid eye disease appeared to primarily manifest as evaporative dry eye disease in a cohort of treatment-naive patients in China, according to study results published in Journal of Clinical Medicine.

VRDN-001 demonstrated positive preliminary results in the treatment of chronic thyroid eye disease in an ongoing phase 1/2 clinical trial, according to a press release from Viridian Therapeutics.